key: cord-0988246-76svuj1q
authors: Eyllon, Mara; Dang, Alexander P.; Barnes, J. Ben; Buresh, John; Peloquin, Gabrielle D.; Hogan, Annika C.; Shimotsu, Scott T.; Sama, Susan R.; Nordberg, Samuel S.
title: Associations between psychiatric morbidity and COVID-19 vaccine hesitancy: An analysis of electronic health records and patient survey
date: 2021-12-07
journal: Psychiatry Res
DOI: 10.1016/j.psychres.2021.114329
sha: 3e45a08921bd64b0d3fa3a3d125e2459dca702fb
doc_id: 988246
cord_uid: 76svuj1q

Psychiatric illness confers significant risk for severe COVID-19 morbidity and mortality; identifying psychiatric risk factors for vaccine hesitancy is critical to mitigating risk in this population. This study examined the prevalence of vaccine hesitancy among those with psychiatric illness and the associations between psychiatric morbidity and vaccine hesitancy. Data came from electronic health records and a patient survey obtained from 14,365 patients at a group medical practice between February and May, 2021. Logistic regression was used to calculate odds for vaccine hesitancy adjusted for sociodemographic characteristics and physical comorbidity. Of 14,365 participants 1,761 (12.3%) participants reported vaccine hesitancy. Vaccine hesitancy was significantly more prevalent among participants with substance use (29.6%), attention deficit and hyperactivity (23.3%), posttraumatic stress (23.1%), bipolar (18.0%), generalized anxiety (16.5%), major depressive (16.1%), other anxiety (15.5%), and tobacco use disorders (18.6%), and those previously infected with COVID-19 (19.8%) compared to participants without these disorders. After adjusting for sociodemographic characteristics and physical comorbidities, substance use disorders and tobacco use were significantly associated with increased odds for vaccine hesitancy and bipolar disorder was significantly inversely associated with vaccine hesitancy. Interventions to improve uptake in these populations may be warranted.

 Individuals with psychiatric conditions and substance use disorders have elevated risk for severe COVID-19 morbidity and mortality compared to those without.  Vaccine hesitancy is more prevalent across those with a wide range of psychiatric conditions.  Substance use disorders and tobacco use are independently associated with vaccine hesitancy, controlling for sociodemographic factors.  Interventions embedded in mental health services may improve vaccine uptake among individuals with psychiatric conditions and substance use disorders.

Three vaccines for COVID-19, the disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), have been approved and made widely available for adults in the United States. 1 These vaccines are 50-95% effective for reducing the risk of SARS-CoV-2 infection and 85-100% effective for reducing the risk for symptomatic COVID-19 disease and hospitalization. [2] [3] [4] [5] Despite demonstrated efficacy, safety, and availability, vaccine hesitancy, one's willingness to be vaccinated ranging from acceptance to uncertainty or refusal, despite adequate supply, 6 is common in the United States and worldwide. [7] [8] [9] Understanding the factors associated with vaccine hesitancy and how to address it is therefore an important public health priority.

Psychiatric illness is one such factor. Psychiatric illness is associated with increased risk for severe COVID-19 illness and mortality, independent of physical comorbidity. [10] [11] [12] [13] [14] As of October, 2021, the United States has joined other countries in recognizing this risk and prioritizing those with mental health conditions for COVID-19 vaccination and boosters. Despite this recognition, there is concern that patients with psychiatric conditions may be more susceptible to vaccine hesitancy. In a sample of non-institutionalized patients with mental health conditions in Denmark, 84.8% reported they were willing to be vaccinated for COVID -19 compared to 89.5% of the general population. 15 Research on influenza vaccination in a population of Americans with severe mental illness identified a much larger gap, citing that only 24% of patients had been vaccinated, which was significantly lower than the prevalence of vaccination in the general population at that time. 16 The reasons for COVID-19 vaccine hesitancy among those with psychiatric conditions are not well established. Similar to the general population, vaccine hesitancy may arise from negative perceptions or misinformation about vaccine safety and efficacy. 15, 17 However, this distrust may be amplified by experiences of stigma from healthcare providers or other poor treatment within the healthcare system. 18 Moreover, those with psychiatric conditions may experience socioeconomic and structural barriers, 19 and diminished self-efficacy, which can undermine follow through with vaccination.

While widespread uptake of the COVID-19 vaccine is critical for mitigating the spread of the virus, as of November, 2021 only 59% 20 of American adults have been fully inoculated and between 17% 21 and 42% 7 report that they are uncertain about or resistant to being vaccinated.

Addressing vaccine hesitancy presents a critical challenge to mitigating the spread of COVID-19, establishing broad population herd immunity, and ensuring a safe return to normalcy.

Furthermore, identifying the extent of vaccine hesitancy among adults with psychiatric illness is a critical step to developing strategies and interventions to improve vaccination uptake and reducing related morbidity and mortality in this vulnerable population. 12, 13, 22 To date, research on vaccine hesitancy has focused primarily on sociodemographic characteristics, ideology, and personality traits. 7 15, 29, 35 One study reported that vaccine hesitancy was associated with specific anxieties about COVID-19 infection and health consequences, but not associated with general anxiety or depression as measured by the GAD-2 and PHQ-2. 35 Yet another study identified a small but significant inverse association between self-reported mental health treatment and vaccine hesitancy among Irish participants, but not British participants. 29 While these studies contribute to our nascent understanding of the psychiatric correlates of vaccine hesitancy, they are limited in several ways. First, the validity of the PHQ-2 and GAD-2

is not well established 36, 37 and these brief screening tools may have limited sensitivity.

Furthermore, none of the studies differentiated between specific psychiatric disorders or controlled for objective measures of physical comorbidity leaving the potential for residual confounding.

Critically, this approach may fail to identify heterogeneity in vaccine hesitancy across psychiatric conditions, which is plausible given the variability in symptoms, cognition, behavior, and experiences within the healthcare system. Indeed, some of the research on preventive behavior in response to infectious disease outbreaks and cardiac events, has identified different patterns of behavior associated with different psychiatric symptoms and conditions. For example, several studies have reported that high levels of depressive symptoms are associated with reduced preventive behavior (e.g. social distancing, handwashing, and masking) in response to COVID-19 and SARS. [38] [39] [40] . In a prospective study of patients following myocardial infarction, onset of major depression was associated with diminished preventive health behavior, while the onset of generalized anxiety disorder was associated with increased uptake of preventive behavior. 41 Similarly, in contrast to depression, the majority of studies report significant associations between anxiety symptoms and higher uptake of preventive measures in response to infectious disease outbreaks, [42] [43] [44] [45] though divergent findings have also been reported. 39, 40 These inconsistencies may point to a threshold effect where increased worry and vigilance associated with moderate anxiety may be instrumental for promoting preventive behavior, but at high levels become maladaptive. 44 Along these lines, one study reported that while moderate and high levels of anxiety were both associated with an increase in preventive behavior, the effect of moderate anxiety was much larger. 44 Because the majority of these studies focus on symptoms, which may underly a temporary response to an event or a pervasive condition, their generalizability to clinical levels of anxiety or depression is less clear.

While less-researched, Attention Deficit and Hyperactivity Disorder (ADHD) is associated with non-adherence to COVID-19 safety guidelines, potentially due to deficits in attention and executive function that mediate a higher propensity for risk taking behavior among those with ADHD. 46, 47 In another study, both alcohol and substance use disorders were significantly associated with COVID-19 disregard for social distancing and the belief that the severity of COVID-19 was exaggerated, though the effect sizes were larger among participants with substance use disorders compared to alcohol use disorders. 48 Finally, there is an association between bipolar disorder and poorer uptake of healthy behaviors, 49 though, to our knowledge, this has not been explored in relation to infectious disease prevention.

Given that psychiatric illness confers significant risk for severe COVID-19 illness and mortality and variability in the uptake of preventive measures across psychiatric conditions, here is a critical need to better understand the relationship between these conditions and vaccine hesitancy. To this end, this cross-sectional study examined the associations between psychiatric morbidities extracted from electronic health records (EHR) and vaccine hesitancy data collected in the second wave of a longitudinal survey of primary care patients at a large group medical practice in northeastern United States to address the following objectives:

First, we aimed to estimate the proportion of survey respondents who are hesitant/ resistant to being vaccinated.

Second, we aimed to identify the prevalence of vaccine hesitancy among respondents with diagnosed psychiatric and physical risk factors for COVID-19 disease.

Third, we aimed to examine the associations between psychiatric and physical riskfactors for COVID-19 disease and vaccine hesitancy.

We conducted a cross-sectional study using data from the second wave of a longitudinal study of mental health and wellbeing during the COVID-19 pandemic. The study was conducted at a northeastern multi-specialty group medical practice serving 275,000 adult and pediatric 

To assess vaccine hesitancy, participants were asked if they had received at least one dose of a COVID-19 vaccine. Participants who had not yet received the vaccine were then given a five-level Likert scale question about their intent to be vaccinated. Participants who reported that they were "unsure," "don't know," "probably would not," or "definitely would not" be vaccinated were classified as vaccine hesitant. Those who had received a vaccine and all others were classified as acceptant. Because vaccine hesitancy exists on a continuum ranging from uncertainty to outright resistance and due to the relatively small proportion of vaccine resistant respondents (2.9%), we constructed the vaccine hesitancy category by combining hesitancy and resistance. Psychiatric and physical morbidities were ascertained from the patients' medical records and classified using the ICD-10 (eTable 1). We included major depressive disorder, generalized anxiety disorder, other anxiety disorders, posttraumatic stress disorder (PTSD), attention deficit and hyperactivity disorder (ADHD), alcohol use disorder (AUD), and substance use disorder (SUD). Physical comorbidities were based on known risk factors for COVID-19. 50 We also included current nicotine dependence/tobacco use and clinical overweight/obesity from the EHR, and self-report of a previous COVID-19 infection.

We obtained participants' age, race, and Hispanic ethnicity from the EHR. Age was categorized according to the Center for Disease Control's guidelines based on risk for COVID-19 disease, hospitalization, and death. 51 (Figures 1-3) . All covariates were retained in the models regardless of statistical significance. Log-odds were exponentiated and interpreted as odds ratios with 95% confidence intervals. We conducted multiple imputation by chained equations with the mice package in R 52,53 to obtain missing values for income (37.6%), education (32.8%) , and race (16.4%). The imputation strategy is described in the online supplement. We ran 45 imputations and pooled results using Rubin's rules to obtain estimates and standard errors. 54 All statistical analyses were conducted in R 3.6.1. 55

We (Figure 3 ). Nicotine dependence/tobacco use was associated with vaccine hesitancy (OR 1.44, p<.001). Immunodeficiency was associated with 31% lower odds for hesitancy (p=.03) ( Figure 3 ).

The present study examined the associations between psychiatric morbidity and vaccine hesitancy. Overall, 12.3% of patients reported hesitancy or resistance to receiving a COVID-19

vaccine. In this sample, vaccine hesitancy was more prevalent across all psychiatric morbidities except for alcohol use disorders (AUD), and less prevalent among several physical comorbidities. Substance use disorders (SUD), nicotine dependence/tobacco use (ND/TU) and

previous COVID-19 infection conferred significant odds for vaccine hesitancy when accounting for potentially confounding sociodemographic factors. Contrary to previous research identifying an association between anxiety and increased preventive behavior, we found that vaccine hesitancy was similar across those with anxiety disorders and other conditions. This may be because we used diagnoses which are more sensitive to identifying clinically meaningful levels of anxiety and related impairment rather than natural variation in anxiety levels among otherwise healthy adults.

Our finding that 12.3% of our sample is vaccine hesitant is low relative to nationwide estimates between 32% and 43% reported as of Spring 2020. However, more recent data from the Census Bureau suggests a decline in vaccine hesitancy by March 2021 when 84% of Americans reported they had already been vaccinated or definitely/probably would be vaccinated. 21 This may also reflect relatively higher levels of vaccine acceptance in northeastern states relative to other parts of the United States, as well as the high proportion of college educated participants in our sample.

Medicaid payer type were all associated with hesitancy. Hesitancy was also more prevalent among females, African Americans/Blacks, and Hispanics. In previous research, Blacks have reported significantly greater vaccine hesitancy relative to Whites, 7,28 which has been attributed to medical mistrust stemming from systemic racism. 56, 57 Similarly, in this sample, there was a 12% difference in vaccine hesitancy between Black/African Americans and Whites. However, this disparity is substantially smaller than disparities of 24-28% reported in Spring 2020, 7 , 28 and may reflect increased vaccine acceptance among Blacks through the Winter of 2021, 58 and the high proportion of our sample with college education. Additionally, the proportion reporting vaccine resistance was particularly low in our sample (2.9%), though there were deviations.

Younger respondents and those with lower socioeconomic status (e.g. income, education, and last payor Medicaid) were all slightly more likely to report resistance compared to those in other categories, consistent with the literature. 7, 29 Vaccine resistance was also slightly more prevalent among those with depression, generalized anxiety and bipolar disorder compared to other conditions. Although much of the work to date takes a similar approach to addressing vaccine uncertainty and resistance, future work should identify potential mediators and moderators of resistance as this population may require more tailored interventions.

Given the heightened prevalence of vaccine hesitancy and vulnerability to the negative sequelae of COVID-19 among those with psychiatric illness, addressing vaccine hesitancy is an

important, yet overlooked priority for national and state policymakers. 22 Patients with SUD and TU/ND are more likely to report vaccine hesitancy independent of other socioeconomic factors. This is concerning given SUDs are associated with 9-fold risk for COVID-19 disease and tobacco use is associated with 8-fold risk. 23 These findings align with research identifying poorer engagement in preventive healthcare among those with SUD and tobacco use. 60, 61 Possible explanations for poorer compliance with preventive care include socioeconomic deprivation, challenges prioritizing healthcare over substance use, and stigmatization from medical providers. [62] [63] [64] Strategies for improving vaccine uptake in other populations may provide guidance for improving acceptance among those with psychiatric illness. Simple interventions such as text message reminders to patients eligible for the COVID-19 vaccine can improve uptake by 84%. 65 This can help by removing barriers to finding appointments and scheduling, which has been shown to be effective among individuals with substance use disorders but may also be relevant to other populations. 63 Direct outreach by doctors' offices may also be effective. One study reported that information from doctors was among the most important factors for making health decisions among individuals with history of SUDs. 66 Another study reported that among patients with mental illness, those who received vaccine education from their physician had four-fold odds for obtaining an influenza vaccine. 17 In addition, outreach by mental health professionals may be particularly beneficial as they can tailor vaccine education to their patients' needs 19 and can address psychological and structural barriers to vaccination. In addition, development of shared decision-making tools among providers may educate patients about the benefits of receiving the vaccine. 67, 68 Vaccination clinics embedded in substance use treatment and mental health services may also remove barriers to uptake; embedding a vaccine clinic in a mental healthcare facility improved Td/Tdap vaccination rates by nearly 34% among patients with mental illness. 69 However, many individuals with psychiatric illness or SUD do not receive appropriate medical or mental healthcare and it is important to reach those outside of organized care settings. Possible strategies to reach these vulnerable populations include implementing educational campaigns and vaccine clinics at clean injection sites, detox centers, shelters, and community centers.

These findings also suggest that vaccine hesitancy is greater among those with previous COVID-19 infection and those who are unsure if they were previously infected. Although some research reports low rates of reinfection among previously infected individuals, 70 

for Disease Control. Different COVID-19 Vaccines

How will emerging SARS-CoV-2 variants impact herd immunity?

Interim Estimates of Vaccine Effectiveness of Pfizer-BioNTech and Moderna COVID-19 Vaccines Among Health Care Personnel -33

Covid-19: Moderna vaccine is nearly 95% effective, trial involving high risk and elderly people shows

The BNT162b2 (BioNTech/Pfizer) vaccine had 95% efficacy against COVID-19 ≥7 days after the 2nd dose

Diagnosing the determinants of vaccine hesitancy in specific subgroups: The Guide to Tailoring Immunization Programmes (TIP)

Attitudes Toward a Potential SARS-CoV-2 Vaccine : A Survey of U.S. Adults

COVID-19 Vaccine Hesitancy Worldwide: A Concise Systematic Review of Vaccine Acceptance Rates

Predictors of COVID-19 vaccine hesitancy in the UK household longitudinal study

Increased risk of COVID-19 infection and mortality in people with mental disorders: analysis from electronic health records in the United States

Bidirectional associations between COVID-19 and psychiatric disorder: retrospective cohort studies of 62 354 COVID-19 cases in the USA. The Lancet Psychiatry

Association between mental illness and COVID-19 susceptibility and clinical outcomes in South Korea: a nationwide cohort study. The Lancet Psychiatry

Association of psychiatric disorders with mortality among patients with COVID-19

The Impact of Substance Use Disorder on COVID-19 Outcomes

COVID-19 vaccine willingness amongst patients with mental illness compared with the general population

Factors associated with influenza vaccination decisions among patients with mental illness

Factors associated with influenza vaccination decisions among patients with mental illness

Stigma and trust among mental health service users

Maximizing the Uptake of a COVID-19 Vaccine in People with Severe Mental Illness: A Public Health Priority

Household Pulse Survey COVID-19 Vaccination Tracker

COVID-19 vaccination for people with severe mental illness: why, what, and how? The Lancet Psychiatry

COVID-19 risk and outcomes in patients with substance use disorders: analyses from electronic health records in the United States

Association of a prior psychiatric diagnosis with mortality among hospitalized patients with coronavirus disease 2019 (COVID-19) infection

Barriers to self-management of serious mental illness and diabetes

Increased transmissibility and global spread of SARS-CoV-2 variants of concern as at

Severe mental illness and European COVID-19 vaccination strategies. The Lancet Psychiatry

Determinants of COVID-19 vaccine acceptance in the US

Psychological characteristics associated with COVID-19 vaccine hesitancy and resistance in Ireland and the United Kingdom

COVID-19 vaccine hesitancy in the UK: The Oxford coronavirus explanations, attitudes, and narratives survey (Oceans) II

Knowledge, attitude and acceptance of a COVID-19 vaccine: A global cross-sectional study

The growing vaccine hesitancy: Exploring the influence of the internet

Will they, or won't they? Examining patients' vaccine intention for flu and COVID-19 using the Health Belief Model

COVID-19 vaccination hesitancy in the United States: A rapid national assessment

COVID-19 vaccine hesitancy and related fears and anxiety

Screening for depression in medical settings with the Patient Health Questionnaire (PHQ): A diagnostic meta-analysis

Screening for anxiety disorders with the GAD-7 and GAD-2: A systematic review and diagnostic metaanalysis

Functional Fear Predicts Public Health Compliance in the COVID-19 Pandemic

Immediate Psychological Responses and Associated Factors during the Initial Stage of the 2019 Coronavirus Disease (COVID-19) Epidemic among the General Population in China

COVID-19 preventive behaviours among people with anxiety and depressive symptoms: findings from Japan

Depression and Anxiety Following Myocardial Infarction and Their Inverse Associations with Future Health Behaviors and Quality of Life

Association Between Preventive Behaviour and Anxiety at the Start of the COVID-19 Pandemic in Slovenia

Influenza vaccine uptake, COVID-19 vaccination intention and vaccine hesitancy among nurses: A survey

The impact of community psychological responses on outbreak control for severe acute respiratory syndrome in Hong Kong

Community Responses during Early Phase of COVID-19 Epidemic, Hong Kong

Risk-Taking Behavior in Attention Deficit/Hyperactivity Disorder (ADHD): a Review of Potential Underlying Mechanisms and of Interventions

Background and concurrent factors predicting non-adherence to public health preventive measures during the chronic phase of the COVID-19 pandemic

Substance use and abuse, COVID-19-related distress, and disregard for social distancing: A network analysis

Nutrition and exercise behavior among patients with bipolar disorder1

Hypertension, medications, and risk of severe COVID-19: A Massachusetts community-based observational study

Risk for COVID-19 Infection, Hospitalization, and Death By Age Group | CDC

Multiple imputation by chained equations in R

Multiple Imputation Using R. Zurich

Multiple imputation using chained equations: Issues and guidance for practice

R: A language and environment for statistical computing

An investigation of low COVID-19 vaccination intentions among Black Americans: The role of behavioral beliefs and trust in COVID-19 information sources

You don't trust a government vaccine": Narratives of institutional trust and influenza vaccination among African American and white adults

New Evidence from the Household Pulse Survey: Vaccine Hesitancy Decreased During the First Three Months of 2021

COVID-19 Vaccines for People with Underlying Medical Conditions | CDC

Health behaviors of smokers, ex-smokers, and never smokers in an HMO

Is unhealthy substance use associated with failure to receive cancer screening and flu vaccination? A retrospective cross-sectional study

COVID-19 and persons with substance use disorders: Inequities and mitigation strategies

Multilevel barriers and facilitators to primary care among people who inject drugs

Stigma among health professionals towards patients with substance use disorders and its consequences for healthcare delivery: Systematic review

Behavioral nudges increase COVID-19 vaccinations: Two randomized controlled trials

Letter to the Editor Trust in a COVID-19 vaccine among people with substance use disorders

Shared decision making enhances pneumococcal vaccination rates in adult patients in outpatient care

Can shared decision making address COVID-19 vaccine hesitancy? BMJ Evidence-Based Med. 2021;0

Adult vaccination rates in the mentally ill population: An outpatient improvement project

Assessment of the risk of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) reinfection in an intense reexposure setting

COVID-19 vaccine hesitancy and attitudes in Qatar: A national cross-sectional survey of a migrant-majority population

Risk of SARS-CoV-2 reinfection after natural infection

Assessment of SARS-CoV-2 reinfection 1 year after primary infection in a population in Lombardy, Italy

Assessment of protection against reinfection with SARS-CoV-2 among 4 million PCR-tested individuals in Denmark in 2020: a population-level observational study

Frequently Asked Questions about the COVID-19 Vaccine

We would like to acknowledge Lawrence Garber, MD, Artur Cosquete, and Meagan Fair of Reliant Medical Group for implementing and disseminating the MyChart survey to patients and for setting up the data transfer between Reliant Medial Group and UnitedHealth Group.